Đang chuẩn bị liên kết để tải về tài liệu:
Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: A retrospective study

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Only a few patients with pancreatic ductal adenocarcinoma (PDAC) recurring after curative resection and peri-operative (neoadjuvant and adjuvant) therapy are included in clinical trials of metastatic PDAC. | Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy A retrospective study

TÀI LIỆU LIÊN QUAN

A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma

Competing risk analyses of overall survival and cancer-specific survival in patients with combined hepatocellular cholangiocarcinoma after surgery

A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

Nomogram for predicting the overall survival and cancer-specific survival of patients with extremity liposarcoma: A population-based study

Nomograms predicting the overall survival and cancer-specific survival of patients with stage IIIC1 cervical cancer

Prognostic value of computed tomography characteristics for overall survival in patients with maxillary cancer

The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: A meta-analysis

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: A propensity score matching analysis

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors